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Global metabolic proﬁling of human osteoarthritic synovium
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Osteoarthritis (OA) is a debilitating disease associated with pain and loss of function in numerous dia-
rthrodial joints of the body. Assessments of the severity and/or progression of OA are commonly based
on radiographic stages and pain level, which aren’t always correlated to severity of disease or joint
dysfunction and may be confounded by other factors1. There has been recent interest in identifying
a biochemical signature of OA1 that may be detected in serum, urine, and/or synovial ﬂuid that would
represent repeatable and predictable biomarkers of OA onset and/or progression. The objective of this
study was to use global metabolic proﬁling to identify a distinct metabolic proﬁle for cultured human
synovial tissue from patients with end-stage OA compared to patients with little or no evidence of
disease. While metabolic proﬁles from cultured tissues are not expected to reproduce in vivo proﬁles, it is
expected that perturbations in metabolism caused by end-stage disease would result in differences in
metabolic proﬁles in vitro compared to tissue with little or no evidence of disease. Because metabolomic
perturbations often occur prior to alterations in the genome or proteome, metabolomic analysis possibly
provides an earlier window to an altered biochemical proﬁle for OA onset and/or progression, and may
provide a unique set of potential drug targets. The synoviumwas targeted because it has been implicated
in OA as a mediator of disease progression; osteoarthritic synovium has been demonstrated to express
pro-inﬂammatory cytokines, such as Tumor Necrosis Factor - a (TNF-a), Interleukin-1 b (IL-1b), and IL-62,
suggesting that a diseased synovial lining could produce an ideal set of biomarkers for diagnosing OA
and/or monitoring disease progression. Media from the culture of synovial explants dissected from
diseased human joints (early or end-stage OA) was subjected to global metabolic proﬁling with a liquid
chromatography (LC)/and gas chromatography (GC)/mass spectrophotometry (MS)-based technology
platform. Metabolites were identiﬁed by automated comparison of the ion features in the experimental
samples to a reference library of chemical standard entries developed at Metabolon, Inc (Durham, NC).
Global metabolic proﬁling resulted in the identiﬁcation of 105 distinct compounds across all sample
groups, with 11 compounds showing signiﬁcantly different relative concentrations between end-stage
and no/early disease groups. Metabolites speciﬁc to collagen metabolism, branched-chain amino acid
metabolism, energy metabolism and tryptophan metabolism were amongst the most signiﬁcant
compounds, suggesting an altered metabolic state with disease progression.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Methods, results, and discussion
Synovial tissue samples were collected as discarded tissues
(non-human subjects research) from patients undergoing total
knee arthroplasty for end-stage osteoarthritis (OA) (“end-stage OA”
group, n¼ 11, mean age standard deviation: 67.8 7.7) or from: D.L. Nettles, Department of
1, Durham, NC 27708, USA.
s Research Society International. Ppatients undergoing ligament or meniscal repair with little or no
evidence of OA (“no/early OA” group, n¼ 11, mean age standard
deviation: 18.9 4.8). Tissue samples were not processed from
joints found to have more than one cartilage lesion, greater than
Outerbridge grade 2 in the medial or lateral joint space, or greater
than Outerbridge grade 3 changes on the patella. Samples were
kept sterile upon collection, dissected to 3 3 mm, weighed, and
placed into individual culture tubes containing 2 ml of sterile
culture media (LG-DMEM (Gibco), 10% FBS (Hyclone), 5 ml Pen-
Strep (100 U/100 mg), and 25 mM HEPES buffer). Samples, along
with separate control tubes containing media only (n¼ 8), were
cultured at 37C and 5% CO2 for 48 h in order to allow metabolitesublished by Elsevier Ltd. All rights reserved.
Table II
Metabolites decreased in media with end-stage OA versus early/no OA
Metabolite Pathway Mean fold
change
P-value
P< 0.05
Gamma-glutamylleucine Peptide, glutathione 1.75 <0.001
4-methyl-2-oxopentanoate BCAA 1.59 0.045
5-oxoproline AA, glutathione 1.30 <0.001
Phenylacetlyglycine AA 1.08 0.004
0.05< P< 0.1
3-methyl-2-oxobutyrate BCAA 1.64 0.084
Ornithine Urea cycle, AA 1.41 0.055
Pyridoxate Vitamin B6 1.20 0.092
2-methylbutyroylcarnitine BCAA 1.18 0.087
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frozen at 80C until analysis. Control media was incubated over
the same time course as the other two groups to control for possible
changes occurring in mediametabolites over the incubation period.
All media (conditioned and control) was analyzed using untar-
geted, metabolic proﬁling performed at Metabolon combining
three independent platforms: ultrahigh performance liquid chro-
matography/tandem mass spectrometry (UHLC/MS/MS2) opti-
mized for basic species, UHLC/MS/MS2 optimized for acidic species,
and gas chromatography/mass spectrometry (GC/MS) as previously
described3. In addition, three types of controls were analyzed in
concert with the experimental samples: samples generated from
pooled experimental samples served as technical replicates
throughout the data set, extracted water samples served as process
blanks, and a cocktail of standards spiked into every analyzed
sample allowed instrument performance monitoring.
Metabolites were identiﬁed by automated comparison of the ion
features in the experimental samples to a reference library of
chemical standard entries developed at Metabolon, Inc. Following
log transformation and imputationwith minimum observed values
for each compound, Welch’s two-sample t-tests were used to
identify biochemicals that differed signiﬁcantly between early and
late stage disease groups compared to media control, as well as to
identify biochemicals that differed between the disease stage
groups. An estimate of the false discovery rate (q-value) was
calculated to take into account the multiple comparisons that
normally occur in metabolomic-based studies4.
One hundred ﬁve biochemicals were detected across all condi-
tioned media samples. Of the 11 biochemicals with levels in condi-
tioned media signiﬁcantly different between the end-stage OA and
no/early OA groups, seven were higher in the end-stage OA group
compared to the no/early group (Table I, P< 0.05), while four were
present at lower levels (Table II, P< 0.05). In addition, nine
compounds showed trends towards increased (Table I, 0.05< P< 0.1)
or decreased (Table II, 0.05< P<0.1) expression with end-stage OA.
Among metabolites showing distinct levels in conditioned media of
synovium samples were biomarkers of collagen turnover [prolyl-
hydroxyproline (PHP)], cellular energetics (acetylcarnitine, succinate,
and glutamine), and branched-chain amino acid (BCAA) catabolism
(4-methoxy-2-oxopentanoate and 3-methyl-2-oxobutyrate).
The dipeptide, PHP, is a compound associated with the break-
down of collagen5. Type I and II collagens are compositionally
major components of connective tissue, cartilage, and bone, and
perturbation of collagen biology has been associated with devel-
opment of OA6. The elevated level of PHP in late disease synovialTable I
Metabolites increased in media with end-stage OA versus early/no OA
Metabolite Pathway Mean fold
change
P-value
P< 0.05
Pro-hydroxyproline Collagen degradation 1.60 0.001
Acetylcarnitine Lipid, carnitine, TCA cycle 1.42 0.002
Myo-inositol Lipid, inositol 1.30 <0.001
N-acetylornithine Urea cycle, AA 1.24 0.029
Succinate TCA cycle 1.24 0.015
Glutamine AA, TCA cycle 1.19 <0.001
Urea Urea cycle, AA 1.06 0.03
0.05< P< 0.1
Beta-alanine AA, pyrimidine degradation 1.50 0.055
Uracil Pyrimidine 1.48 0.087
Arabitol Carbohydrate 1.30 0.095
Catechol sulfate Benzoate 1.17 0.015
P-cresol sulfate AA 1.12 0.057
AA¼Amino Acid.tissue conditioned media is consistent with an increased capacity
for proteolysis of the collagen extracellular matrix with advanced
stages of disease, although the speciﬁc isoforms involved in this
proteolysis cannot be known. A second potential marker of collagen
turnover e 4-hydroxyproline e was found to be present in both
conditioned media groups when compared to media controls, yet
did not show a signiﬁcant difference between early and late disease
groups. Elevated levels of both peptides in urine have been shown
to be correlated with bone resorption associated with osteopo-
rosis7, but have not proven to be signiﬁcant markers of joint
breakdown in rheumatic diseases, which also can perturb collagen
metabolism8. Differences in PHP levels detected in the present
study compared to other studies may reﬂect an ability to capture
less stable metabolites through a 48 h period of culture than are
present in body ﬂuids.
A second key difference between early/no and late disease
conditioned media relates to BCAA catabolism. In general, the
cultured synovial tissues acted to increase the amino acid contri-
bution to the media. By contrast, levels observed for tryptophan
and the BCAAs, leucine, isoleucine, and valine, in conditioned
media samples did not differ from control media, while catabolic
products of the BCAAs were evident in both late disease and early/
no disease groups. The ﬁrst-step catabolites of BCAAs (4-methyl-
2-oxopentanoate, 3-methyl-2-oxobutyrate, and 3-methyl-2-oxo-
valerate) were present in all samples from tissue culture, indicating
that their presence in the media is largely via cellular metabolism
and excretion. However, a lower level of these metabolites in media
from the late-stage OA group suggests an alteration in BCAA
metabolismwith disease progression. Recently, the ratio of BCAA to
the amino acid histidine was suggested as a biomarker for OA9. In
that study, increased serum BCAA correlated with radiographic
severity of OA. While we show no differences in the levels of BCAA
or histidine between groups in our study, both studies suggest
a role for altered BCAA metabolism in OA and may prove to be
a useful marker of disease progression.
The Tricarboxylic Acid (TCA) cycle is a key biochemical pathway
for the oxidative conversion of carbohydrates for the generation of
cellular energy. Carbon contribution to the TCA cycle originates
primarily through the metabolism of glucose to pyruvate but also
through the anaplerotic contribution of glutamine to the TCA
intermediate alpha-ketoglutarate. Indeed, both tissue sample
groups signiﬁcantly depleted the culture media of precursors
glucose and pyruvate, and generated elevated media levels of
lactate, a product of pyruvate, as well as several TCA intermediates
(citrate, cis-aconitate, and malate). However, in late disease culture
media, signiﬁcantly elevated levels for succinate and glutamine
suggest that theses cultures display altered energy metabolism
compared to early disease cultures. Glutamine is important for
oxidative metabolism; thus, elevated glutamine suggests altered
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glutamine could also point to a decrease in glycosaminoglycan
(GAG) production, as glutamine is required for the production of
GAG10. Although not reaching signiﬁcance, levels for additional TCA
intermediates also trend in the direction of reduced oxidative
energy metabolism with disease (Table I). Altered metabolic
proﬁles in urine and synovial ﬂuid from OA patients have also
suggested a role for altered energy metabolism in OA11,12.
Reduced oxidative metabolism in late disease cultures also
may be indicated by the elevated media levels of acetylcarnitine
observed for this group (Table I). Carnitine is a small polar
molecule that is required to shuttle long-chain fatty acids across
the inner mitochondrial membrane for beta-oxidation and also as
a regulator of energy metabolism through control of the Acyl-
CoA:CoA ratio. For example, in the mitochondrial matrix, carni-
tine can facilitate glucose metabolism by accepting the acyl group
from acyl-CoAs allowing the key cofactor CoA to participate in
additional reactions. Higher acetylcarnitine in the media from late
disease tissue culture suggests that acetyl-CoA is not being
effectively moved through the TCA cycle. In a recent proteomic
study of mitochondria from normal or osteoarthritic chon-
drocytes, of 22 mitochondrial proteins identiﬁed as being altered
in OA, 26% were associated with pyruvate metabolism and/or
the TCA cycle, also suggesting decreased energy metabolism in
diseased cells13.
In addition to biochemical differences between early and late
disease states, 42 biochemicals were signiﬁcantly elevated or
decreased in media from both conditioned media groups compared
to the media controls. These compounds provide some information
about synovium metabolism, baseline or that associated with
pathology, both mild and advanced. Of note, kynurenine, a metab-
olite of tryptophan that was signiﬁcantly elevated in both tissue
sample groups, is responsive to immune and inﬂammatory stim-
ulation and is altered in a variety of human disorders and
diseases14. Elevated tryptophan metabolism and kynurenine levels
have also been shown in primary synovial cell cultures in response
to elevated interferon-g, suggesting altered or increased trypto-
phanmetabolism in response to inﬂammatory cytokines associated
with arthritis15. In this instance, further understanding of the
impact of disease progression on tryptophan/kynurenine metabo-
lism could beneﬁt from further analysis of this pathway in synovial
and/or cartilage cells.
This study has two key limitations. First, the distinct age groups
represented in the late-stage disease and no/early disease groups
are potentially confounding. Metabolism, and notably BCAA
metabolites, are known to show age-dependent alterations3 and
further study would be required to unequivocally distinguish
disease- from age-related alterations in metabolism. Second, the
study is limited by the lack of a true healthy control group.
Although the patients in the no/early OA group had substantially
less intra-articular pathology, the nature of their injuries does not
preclude intra-articular inﬂammation, as several studies have
demonstrated synovial pathology even in early OA2. It is likely that
a healthy control group would provide for an increased ability to
ﬁnd a greater number of distinctly different metabolites associated
with OA onset and progression.
In summary, global metabolic proﬁling of conditioned media
from explanted synovial tissue suggests a distinct metabolic proﬁle
for end-stage OA. Metabolites involved with collagen degradation,
amino acid/BCAA catabolism, energy metabolism, and lipid and
carbohydratemetabolismwere found to be signiﬁcantly different in
media from synovial tissue cultures from patients with end-stage
OA compared to those of patients with little or no evidence of
disease. These metabolites may serve as novel biomarkers for OA
diagnosis or to monitor disease progression.Author contributions
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